Tag: Anticoagulants
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19
For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants
Prophylactic Anticoagulation Aids Hospitalized COVID-19 Patients
Prophylactic-dose anticoagulation, but not treatment-dose anticoagulation, associated with lower 60-day mortality
Guidance Issued for Managing CVST After COVID-19 Vaccination
CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
Adding Aspirin May Up Risk for Patients on DOAC for A-Fib/VTE
Among patients with a-fib and/or VTE, about one-third received ASA in addition to a DOAC with no clear indication for ASA
Prophylactic Anticoagulation May Cut COVID-19 Mortality
Lower 30-day mortality, no increase in serious bleeding events seen among COVID-19 inpatients receiving early prophylactic anticoagulation
Early Anticoagulation May Not Up Survival in Severe COVID-19
Venous thromboembolism seen in 6.3 percent and major bleeding seen in 2.8 percent of critically ill COVID-19 patients
Full-Dose Heparin May Aid Moderately Ill COVID-19 Patients
Interim results show improvement in primary end point of need for ventilation, other organ-supportive interventions
Anticoagulants Not Tied to Higher Risk for GI Bleed in COVID-19
3 percent of hospitalized COVID-19 patients experience gastrointestinal bleeding
Ongoing Anticoagulant Use Does Not Avert Severe COVID-19
No reduction seen in risks for hospital admission, intensive care unit admission, or death due to COVID
